Treprostinil (L606) vs Treprostinil (Yutrepia, Liquidia)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Treprostinil (L606)

Developed by Liquidia Corporation under a licence from Pharmosa Biopharm Inc.

Phase 3 in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin analogue, inhaled liposomal)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Treprostinil (Yutrepia, Liquidia)

Marketed by Liquidia Corporation

Approved in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin analogue, inhaled dry powder)
Weak signal

NCT03399604 · Phase 3 · completed

The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.

Next expected readout: May 2027 · NCT07759804 (registry estimate)

Reported efficacy

Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)

Result source: NCT03399604

Results for Pulmonary Arterial Hypertension

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Treprostinil (L606): no structured comparison results are available for Pulmonary Arterial Hypertension.

Available safety results

Treprostinil (Yutrepia, Liquidia)

Dropout rate
—LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
24%LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Discontinued due to AEs
—LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
—LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Serious AEs
12.4%LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
—LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Most frequent reported AEs
cough 33.9%
headache 19%
upper respiratory tract infection 14.9%
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (L606)'s landscape · Treprostinil (Yutrepia, Liquidia)'s landscape